RAFAEL HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
RAFAEL HOLDINGS, INC. (RFL) reported Net Income (Loss) Available to Common Stockholders, Basic of -$9.01 million for the 3-month period ending 2024-10-31, per its 10-Q filed 2024-12-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-12-20
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-10-31 was -$9.01M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-07-31 was -$4.47M, a 466.53% decline year-over-year.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-04-30 was -$32.35M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-01-31 was $6.05M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$34.41M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$1.88M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$124.66M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$24.54M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2024-10-31 | -$9.01M 10-Q · filed 2024-12-11 | -$13.47M derived: sum of 2 quarters · filed 2024-12-20 | -$45.83M derived: sum of 3 quarters · filed 2024-12-20 | -$39.78M derived: sum of 4 quarters · filed 2024-12-20 | |
| 2024-07-31 | -$4.47M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | -$36.82M derived: sum of 2 quarters · filed 2024-12-20 | -$30.77M derived: sum of 3 quarters · filed 2024-12-20 | -$34.41M 10-K/A · filed 2024-12-20 | |
| 2024-04-30 | -$32.35M 10-Q · filed 2024-06-14 | -$26.30M derived: sum of 2 quarters · filed 2024-06-14 | -$29.94M 10-Q · filed 2024-06-14 | -$28.72M derived: sum of 4 quarters · filed 2024-12-20 | |
| 2024-01-31 | $6.05M 10-Q · filed 2024-03-14 | $2.41M 10-Q · filed 2024-03-14 | $3.63M derived: sum of 3 quarters · filed 2024-12-20 | $2.19M derived: sum of 4 quarters · filed 2024-12-20 | |
| 2023-10-31 | -$3.64M 10-Q · filed 2024-12-11 | -$2.42M derived: sum of 2 quarters · filed 2024-12-20 | -$3.86M derived: sum of 3 quarters · filed 2024-12-20 | -$7.11M derived: sum of 4 quarters · filed 2024-12-20 | |
| 2023-07-31 | $1.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | -$218.00K derived: sum of 2 quarters · filed 2024-12-20 | -$3.47M derived: sum of 3 quarters · filed 2024-12-20 | -$1.88M 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | -$1.44M 10-Q · filed 2024-06-14 | -$4.69M derived: sum of 2 quarters · filed 2024-06-14 | -$3.10M 10-Q · filed 2024-06-14 | -$7.88M derived: sum of 4 quarters · filed 2024-06-14 | |
| 2023-01-31 | -$3.25M 10-Q · filed 2024-03-14 | -$1.66M 10-Q · filed 2024-03-14 | -$6.44M derived: sum of 3 quarters · filed 2024-03-14 | -$11.97M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-10-31 | $1.59M 10-Q · filed 2023-12-14 | -$3.19M derived: sum of 2 quarters · filed 2023-12-14 | -$8.72M derived: sum of 3 quarters · filed 2023-12-14 | -$11.04M derived: sum of 4 quarters · filed 2023-12-14 | |
| 2022-07-31 | -$4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | -$10.31M derived: sum of 2 quarters · filed 2023-10-30 | -$12.63M derived: sum of 3 quarters · filed 2023-10-30 | -$124.66M 10-K · filed 2023-10-30 | |
| 2022-04-30 | -$5.53M 10-Q · filed 2023-06-13 | -$7.85M derived: sum of 2 quarters · filed 2023-06-13 | -$119.87M 10-Q · filed 2023-06-13 | -$132.25M derived: sum of 4 quarters · filed 2023-06-13 | |
| 2022-01-31 | -$2.32M 10-Q · filed 2023-03-14 | -$114.34M 10-Q · filed 2023-03-14 | -$126.72M derived: sum of 3 quarters · filed 2023-03-14 | -$129.28M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2021-10-31 | -$112.02M 10-Q · filed 2022-12-13 | -$129.32M 10-Q · filed 2021-12-15 | -$124.40M derived: sum of 2 quarters · filed 2022-12-13 | -$126.96M derived: sum of 3 quarters · filed 2022-12-13 | -$135.12M derived: sum of 4 quarters · filed 2022-12-13 |
| 2021-07-31 | -$12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | -$14.93M derived: sum of 2 quarters · filed 2022-10-31 | -$23.10M derived: sum of 3 quarters · filed 2022-10-31 | -$24.54M 10-K · filed 2022-10-31 | |
| 2021-04-30 | -$2.55M 10-Q · filed 2022-06-14 | -$10.72M derived: sum of 2 quarters · filed 2022-06-14 | -$12.16M 10-Q · filed 2022-06-14 | ||
| 2021-01-31 | -$8.16M 10-Q · filed 2022-03-17 | -$9.61M 10-Q · filed 2022-03-17 | |||
| 2020-10-31 | -$1.45M 10-Q/A · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |